2008
DOI: 10.1185/030079908x260925
|View full text |Cite
|
Sign up to set email alerts
|

Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

18
137
0
6

Year Published

2009
2009
2017
2017

Publication Types

Select...
6
4

Relationship

0
10

Authors

Journals

citations
Cited by 228 publications
(161 citation statements)
references
References 30 publications
18
137
0
6
Order By: Relevance
“…Result with present study is comparable to the study conducted by Itamar [16] which reveals Sitagliptin significantly reduced HbA1c compared with metformin monotherapy (p<0.001).The net improvement in HbA1c was -1.0% at both 18 and 30 weeks, and a significantly greater proportion of patients treated with Sitagliptin achieved HbA1c<7.0% by the end of the study (22.1% vs. 3.3%, p<0.001).The proportion of patients meeting the goal of HbA1c< 7.0% was also analyzed.…”
Section: Discussionsupporting
confidence: 82%
“…Result with present study is comparable to the study conducted by Itamar [16] which reveals Sitagliptin significantly reduced HbA1c compared with metformin monotherapy (p<0.001).The net improvement in HbA1c was -1.0% at both 18 and 30 weeks, and a significantly greater proportion of patients treated with Sitagliptin achieved HbA1c<7.0% by the end of the study (22.1% vs. 3.3%, p<0.001).The proportion of patients meeting the goal of HbA1c< 7.0% was also analyzed.…”
Section: Discussionsupporting
confidence: 82%
“…They showed a decrease of 0.66% to 1.9% [98][99][100][101]. Vildagliptin in combination with metformin reduced mean HbA1c by 0.44%-0.9%, while saxagliptin combined with metformin caused a decrease of 0.58% to 2.5% (for doses between 2.5 mg and 10 mg) [102][103][104][105][106][107].…”
Section: Incretin Therapy In More Advanced Stages Of Type 2 Diabetes mentioning
confidence: 96%
“…Induló terápiaként metformint szedőkben a hozzáadott szitagliptin a vizsgálat 30. hetére további 1%-os HbA 1c -csökkenést eredményezett [18], ugyanakkor kedvezően alakult az éhomi és az étkezés utáni vércukorszint is.…”
Section: A Metformin éS a Szitagliptin Szinergista Hatásaiunclassified